Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.71 |
| ▸ | MAOB | P27338 | 3/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312732 | 0.91 | ACHE (0.59) | ACHEKMT2A | |
| SCHEMBL3308921 | 0.89 | MAOB (0.83) | ACHEMAOBMAOAPKMKMT2A | |
| SCHEMBL3318038 | 0.88 | EGFR (0.76) | ACHEMAOBMAOAPKMKMT2A | |
| SCHEMBL3319419 | 0.87 | KDM4E (0.68) | ACHEMAOBMAOAKMT2A | |
| SCHEMBL3314904 | 0.87 | ACHE (0.71) | ACHEMAOBMAOAPKMKMT2A | |
| SCHEMBL3314530 | 0.87 | MAOB (0.83) | ACHEMAOBMAOAPKMKMT2A | |
| SCHEMBL3314726 | 0.85 | KDM4E (0.69) | ACHEMAOBMAOAKMT2A | |
| SCHEMBL8198693 | 0.84 | RAB9A (0.55) | ACHEMAOBMAOAKMT2ANPC1 | |
| SCHEMBL16181219 | 0.84 | MAOB (0.74) | ACHEMAOBMAOAPKMKMT2A | |
| SCHEMBL23052467 | 0.84 | MAOB (0.71) | ACHEMAOBMAOAPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | PDE4A, PDE4B, PDE4C | ACHE 572/4885MAOB 233/4885MAOA 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.